SGLT2 Inhibitors Raise Urinary Yeast Rates Without Increasing UTI Hospitalizations
A large Israeli study links SGLT2 inhibitors to more yeast-positive urine cultures, but not more hospitalizations for urinary infections.
Summary
SGLT2 inhibitors help treat diabetes, heart failure, and kidney disease, but their effects on urinary infections remain a concern. Researchers compared Israeli adults starting these drugs with adults starting GLP-1 receptor agonists. Yeast-positive urine cultures were more frequent with SGLT2 inhibitors: about three times as frequent in adults with diabetes and nearly eight times as frequent in those without diabetes, although the latter estimate was imprecise. Some bacteria were also detected more often, but the major bacterial group responsible for urinary infections showed no increased rate. Hospitalizations for urinary infections remained uncommon and did not increase. These findings support continued treatment when indicated, while highlighting yeast in urine as a safety issue needing further study. Positive cultures do not necessarily indicate symptomatic infection. This observational study cannot establish causation, and this summary uses only the abstract.
Detailed Summary
SGLT2 inhibitors help manage diabetes and are also used for heart failure and kidney disease. Because these drugs increase sugar in urine, researchers examined whether they change urinary infection patterns. The findings suggest a specific increase in yeast detection, rather than a broad increase in bacteria or hospitalizations for urinary infections.
Researchers analyzed Israeli health records from 2015 through 2024, comparing adults starting SGLT2 inhibitors with adults starting GLP-1 receptor agonists. The analysis included 153,660 SGLT2 inhibitor initiators and 172,262 comparator initiators. They used statistical matching to improve group comparability and examined participants with and without diabetes, accounting separately for documented urinary infections during the preceding two years.
Among adults with diabetes, SGLT2 inhibitors were associated with 3.31 times the rate of yeast-positive urine cultures compared with GLP-1 drugs. Among adults without diabetes, the estimated rate was 7.76 times higher, although uncertainty was substantial. Cultures containing Gram-positive bacteria were also more frequent. Gram-negative bacteria, a major cause of urinary infections, were less frequent in adults with diabetes and showed no clear increase in those without diabetes.
Overall positive cultures were less frequent among participants with diabetes, but this difference disappeared in those without a recent urinary infection. Positive cultures were modestly more frequent among participants without diabetes. Hospitalizations for urinary infections remained uncommon, with a lower relative rate in adults with diabetes and no clear difference in those without diabetes. These results support continued use when indicated.
However, yeast in urine does not necessarily mean a symptomatic infection requiring treatment. Patients should discuss urinary symptoms with their clinician rather than stop prescribed medication independently. This observational study cannot establish causation, and differences in prescribing or urine testing could affect results. Absolute event rates were not provided in the abstract. This summary is based on the abstract only, not full-text review.
Key Findings
- Yeast-positive urine culture rates were 3.31 times higher with SGLT2 inhibitors in adults with diabetes versus GLP-1 receptor agonists.
- Without diabetes, yeast-positive culture rates were 7.76 times higher, but the confidence interval was wide: 2.34–47.99.
- Gram-positive bacterial culture rates increased modestly; Gram-negative bacterial culture rates did not increase in either diabetes group.
- UTI hospitalization rates were lower with diabetes and showed no clear difference without diabetes; hospitalizations remained uncommon.
- A positive urine culture does not necessarily indicate symptomatic infection; discuss symptoms with a clinician rather than independently stopping medication.
Methodology
Researchers conducted parallel propensity score-matched, active-comparator, new-user cohort studies using Clalit Health Services records in Israel from 2015–2024. They compared SGLT2 inhibitor and GLP-1 receptor agonist initiators using Poisson regression, with separate analyses by diabetes status and documented UTI history during the preceding two years.
Study Limitations
This summary is based on the abstract only, not a full-text review. The observational design cannot establish causation, and residual confounding or differences in urine testing could influence the associations. Absolute event rates and detailed symptom information were not provided, and estimates for yeast-positive cultures and hospitalization in adults without diabetes were imprecise.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: